Merck lifts full-year forecast as Keytruda sales soar
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St indexes climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Strategy stock jumps 7% as firm shifts to active capital management
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Merck (MRK) PT Raised to $120 at Cantor Fitzgerald
October 27, 2022 12:47 PM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Merck (NYSE: MRK) to $120.00 (from $107.00) while maintaining an Overweight rating.
The analyst commented, ". Post a 3Q22 sales and EPS beat relative to FactSet consensus, we are reiterating our Overweight (OW) rating. We are... More
